Maisa’ M. Darwish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maisa’ M. Darwish has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Alkhawaldeh
School of Educational Sciences\ The University of Jordan\ Jordan
1 shared publication - Duaa K. Albadawi
Department of Medical Applied Sciences, Zarqa University College, Al-Balqa Applied University, Salt 19117, Jordan
1 shared publication - Iyad Y. Natsheh
Department of Allied Medical Sciences, Zarqa University College, Al-Balqa Applied University, Zarqa P.O. Box 313, Jordan
1 shared publication - Majd M. Alsaleh
Department of Allied Medical Sciences, Zarqa University College, Al-Balqa Applied University, Zarqa P.O. Box 313, Jordan
1 shared publication - Mohammad Jamal Amer Shammout
Chemistry Department, Faculty of Science, Applied Science Private University, Amman, Jordan
1 shared publication
Latest Publications
- Open Access
- 16 January 2024
- Published by Aboutscience Srl in Drug Target Insights
- Vol. 18 (1) , 8-19
The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields
Drug repurposing is a strategic endeavor that entails the identification of novel therapeutic applications for pharmaceuticals that are already available in the market. Despite the advantageous nature of implementing this particular strategy owing to its cost-effectiveness and efficiency in reducing the time required for the drug discovery process, it is essential to bear in mind that there are various factors that must be meticulously considered and taken into account. Up to this point, there has been a noticeable absence of comprehensive analyses that shed light on the limitations of repurposing drugs. The primary aim of this review is to conduct a thorough illustration of the various challenges that arise when contemplating drug repurposing from a clinical perspective in three major fields—cardiovascular, cancer, and diabetes—and to further underscore the potential risks associated with the emergence of antimicrobial resistance (AMR) when employing repurposed antibiotics for the treatment of noninfectious and infectious diseases. The process of developing repurposed medications necessitates the application of creativity and innovation in designing the development program, as the body of evidence may differ for each specific case. In order to effectively repurpose drugs, it is crucial to consider the clinical implications and potential drawbacks that may arise during this process. By comprehensively analyzing these challenges, we can attain a deeper comprehension of the intricacies involved in drug repurposing, which will ultimately lead to the development of more efficacious and safe therapeutic approaches.
- 16 January 2024
- Published by Aboutscience Srl in Drug Target Insights
- Vol. 18 (1) , 8-19
Open AccessThe dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields
Drug repurposing is a strategic endeavor that entails the identification of novel therapeutic applications for pharmaceuticals that are already available in the market. Despite the advantageous nature of implementing this particular strategy owing to its cost-effectiveness and efficiency in reducing the time required for the drug discovery process, it is essential to bear in mind that there are various factors that must be meticulously considered and taken into account. Up to this point, there has been a noticeable absence of comprehensive analyses that shed light on the limitations of repurposing drugs. The primary aim of this review is to conduct a thorough illustration of the various challenges that arise when contemplating drug repurposing from a clinical perspective in three major fields—cardiovascular, cancer, and diabetes—and to further underscore the potential risks associated with the emergence of antimicrobial resistance (AMR) when employing repurposed antibiotics for the treatment of noninfectious and infectious diseases. The process of developing repurposed medications necessitates the application of creativity and innovation in designing the development program, as the body of evidence may differ for each specific case. In order to effectively repurpose drugs, it is crucial to consider the clinical implications and potential drawbacks that may arise during this process. By comprehensively analyzing these challenges, we can attain a deeper comprehension of the intricacies involved in drug repurposing, which will ultimately lead to the development of more efficacious and safe therapeutic approaches.